Evidence mapPaperPMID 41089283Full record

ReviewFrontiers in endocrinology2025

Understanding triglyceride glucose-body mass index: implications for diabetes and cardiovascular disease management.

Shunping Zhou, Rong Guo

Abstract readReview
In one paragraph

Review in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Shunping ZhouDepartment of Cardiology, Yangpu Hospital, Tongji University School of Medicine, Shanghai, Shanghai, China.
Rong GuoDepartment of Cardiology, Yangpu Hospital, Tongji University School of Medicine, Shanghai, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This article focuses on the Triglyceride-Glucose Body Mass Index (TyG-BMI) in diabetes and its associated cardiovascular complications. It elaborates on the basic concepts, current clinical practices, technological advancements, controversies, challenges, and future directions related to TyG-BMI. By integrating the findings from numerous studies, we aimed to provide a comprehensive understanding of the role of TyG-BMI in diabetes and cardiovascular disease research, diagnosis, and treatment, highlighting its significance and potential for improving the management of diabetic cardiovascular health.

Indexed as

Blood GlucoseBody Mass IndexCardiovascular DiseasesDiabetes MellitusDiabetes Mellitus, Type 2TriglyceridesDisease ManagementHumansBlood GlucoseTriglyceridescardiovascular diseasediabetesinsulin resistancemortalitytriglyceride glucose-body mass index

Identifiers

PMID41089283
PMCPMC12515649

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.